BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Cerus Corporation 

2411 Stanwell Drive

Concord  California  94520   U.S.A.
Phone: 925-288-6000 Fax: 925-288-6001


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Medical Device


Collaborations

MedImmune 





 Company News
FDA Green Lights Cerus Corporation (CERS) System To Cut Blood Transfusion Infections 12/17/2014 6:59:22 AM
FDA Accepts IDE Supplement For Cerus Corporation (CERS)'s INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma 11/21/2014 10:48:05 AM
Cerus Corporation (CERS) Reports Third Quarter 2014 Results 11/5/2014 9:52:15 AM
Cerus Corporation (CERS) Announces Agreement With Kawasumi Laboratories, Inc. For The Development Of INTERCEPT Platelets Kits In Japan 10/29/2014 8:44:24 AM
American Red Cross To Participate In Cerus Corporation (CERS)' IDE Study To Address Chikungunya And Dengue Blood Safety Risks 10/23/2014 10:13:43 AM
Cerus Corporation (CERS) To Release Third Quarter 2014 Results On November 4, 2014 10/22/2014 9:53:20 AM
Cerus Corporation (CERS) Submits Compassionate Use IDE Supplement For INTERCEPT Blood System Treatment Of Ebola Convalescent Plasma 10/20/2014 7:18:26 AM
FDA Accepts IDE Submission By Cerus Corporation (CERS) Making The INTERCEPT Blood System Available To Address Chikungunya And Dengue Blood Safety Risks 10/7/2014 8:22:47 AM
Cerus Corporation (CERS) And Biomedica Foscama Group S.P.A. Enter Distribution Agreement For The INTERCEPT Blood System In Italy 9/11/2014 8:04:51 AM
Cerus Corporation (CERS) Submits IDE Supplement To Make INTERCEPT Platelets Available Pre-Approval In U.S. Areas At Risk From Outbreaks Of Chikungunya And Dengue 9/10/2014 10:50:09 AM
12345678910...